Medulloblastoma (MB) results from aberrant development of cerebellar neurons in which altered hedgehog (Hh) signalling plays a major role. We investigated the possible influence of Hh signalling on ErbB-receptor expression in MB, in particular that of the ErbB-4 CYT-1 and CYT-2 isoforms generated by alternative splicing of the cytoplasmic domain. ErbB-4 expression was downregulated in Hh-induced MBs from Patched-1 þ /À mice. Hh signalling (reflected by enhanced expression of the Gli1 transcription factor) inhibited ErbB-4 expression in mouse cerebellar granule progenitors and human MB cells. Analysis of 26 human primary MBs revealed a subset of 11 tumors characterized by low Gli1 levels, upregulated ErbB-4 expression and increased CYT-1:CYT-2 ratios. Interestingly, CYT-1 and Gli1 levels were inversely correlated. ErbB-4 CYT-1 and CYT-2 had different phenotypic effects in cultured MB cells: in response to neuregulin treatment, CYT-2 overexpression inhibited proliferation whereas CYT-1, which includes a phosphatidylinositol 3-kinase (PI3K)-binding site that is missing in CYT-2, enhanced resistance to starvation-and etoposide-induced apoptosis by activating PI3K/Akt signalling. CYT-1:CYT-2 ratios displayed correlation with tumor histotype and ErbB-2 levels, which are established prognostic indices for MB. These findings demonstrate that low-level Hh signalling in human MB is associated with the selective maintenance of high ErbB-4 CYT-1 expression, an alteration that exerts tumor-promoting effects.
Introduction
Medulloblastoma (MB) is the most common brain malignancy in childhood. It is the result of aberrant development of cerebellar granule cell progenitors (GCPs) characterized by deregulated proliferation and differentiation (Ruiz i Altaba et al., 2002) . GCP development is critically regulated by signalling through the hedgehog (Hh) pathway (Martı`and Bovolenta, 2002; Ruiz i Altaba et al., 2002) . Inappropriate activation of Hh signals resulting in enhanced expression of the transcription factor, Gli1, has been reported in MB (Ruiz i Altaba et al., 2002) . It has been attributed to genetic defects in components of the Hh pathway or loss of other Hh signalling checkpoints, such as those mapping to chromosome 17p, a region that is frequently deleted in human MB (reviewed by Ferretti et al., 2005) .
The ErbB family of receptors also plays roles in both development and tumorigenesis (Yarden and Sliwkowski, 2001) . Cerebellar expression of ErbB-4 in humans and mice is high during early development and decreases in adulthood (Ozaki et al., 1998; Gilbertson et al., 2001; Fox and Kornblum, 2005) . Interaction between ErbB-4 and its ligand, neuregulin, is highly important for GCP development and maturation (Rieff et al., 1999) , and defects in the cerebellar architecture are observed in À/À /HER4 heart mice genetically rescued from lethality (Tidcombe et al., 2003) . Interpretation of biological data on ErbB-4 is complicated by the existence of four ErbB-4 isoforms, which are generated by alternative exon splicing. They are characterized by different activation mechanisms, different capacities for coupling to specific signalling pathways and, consequently, different in vivo functions. Insertion of alternative amino acids in the extracellular juxtamembrane (JM) region of ErbB-4 gives rise to the cleavable JM-a isoform, which transmits signals to the cytoplasm or nucleus, and the non-cleavable variant, ErbB-4 JM-b, whose signals are confined to the plasma membrane (Elenius et al., 1997; Ni et al., 2001; Carpenter, 2003) . Alternative splicing of the ErbB-4 cytoplasmic domain is responsible for a second pair of isoforms characterized by the maintenance (cytoplasmic isoform 1, CYT-1) or loss of a phosphatidylinositol 3-kinase (PI3K)-binding site (Elenius et al., 1999) . Although both cytoplasmic isoforms can couple to the Shc-MAPK pathway, only CYT-1 is capable of activating antiapoptotic PI3K/Akt signalling. For this reason, cyt-2 expression is associated with reduced resistance to starvation-induced apoptosis compared with that conferred by CYT-1 (Elenius et al., 1999; Kainulainen et al., 2000) .
Although ErbB-4 expression has been reported in MB, its role in the behavior of this tumor (and others) is still poorly understood. Expression of ErbB-2 in MB, alone or together with ErbB-4, is associated with a poor prognosis (Gilbertson et al., 1997 (Gilbertson et al., , 1998 Gajjar et al., 2004) . However, a recent study (Junttila et al., 2005) revealed that, although ErbB-4 is expressed in estrogenreceptor-positive breast cancers, which have a relatively favorable prognosis, nuclear translocation of the intracellular domain of ErbB-4 is associated with poor survival in these patients. In almost all tissues examined thus far (normal and pathological), all four ErbB-4 isoforms are expressed, and this suggests that appropriate ErbB-4 signalling may depend largely on the maintenance of equilibrium among their expression levels (Junttila et al., 2000 (Junttila et al., , 2003 Carpenter, 2003) . A higher frequency of ErbB-4 JM-a compared to JM-b has been described in MB (Gilbertson et al., 2001) , but the expression patterns and roles of the cytoplasmic ErbB-4 isoforms in MB have yet to be investigated.
In this report, we demonstrate that ErbB-4 expression is downregulated in Hh-induced MBs from Ptc1 þ /À mice, and that Hh signalling diminishes in vitro CYT-1 and CYT-2 expression in mouse cerebellar GCPs and in human MB cells. However, in a subset of human MBs characterized by low-level Hh signalling, we documented selective overexpression of ErbB-4 CYT-1 resulting in an increased CYT-1:CYT-2 ratio. These findings suggest the existence of an alternative tumorigenic pathway based on the selective maintenance of high expression of the ErbB-4 CYT-1 isoform in the absence of Hh signals.
Results
Downregulation of the expression of ErbB-4 cytoplasmic isoforms in Hh-dependent mouse MB To investigate the possible influence of Hh signalling on ErbB-4 expression during MB tumorigenesis, we used the Ptc1 þ /À mouse model, which reproduces MB caused by Hh pathway activation (Hahn et al., 1998; Pazzaglia et al., 2002) . Reverse transcription-polymerase chain reaction (RT-PCR) analysis of 14 tumors confirmed the presence of active Hh signalling reflected by increased Gli1 expression and revealed significant downregulation of both the CYT-1 and CYT-2 isoforms of ErbB-4 ( Figure 1a ). These observations suggested that Hh negatively regulates ErbB-4 expression. In immunohistochemical studies of GCPs in the external germinal layer (EGL) of the cerebella from neonatal Ptc1 þ /À mice, the expression of ErbB-4 and Gli1 proteins appeared to be mutually exclusive: Gli1-positive cells were predominantly localized in the outer EGL whereas ErbB-4 staining was mainly confined to inner EGL cells ( Figure 1b) . Next, we treated cultured cerebellar GCPs isolated from postnatal day 4 (P4) CD1 control mice with sonic hedgehog (Shh). The enhanced Gli1 expression and reduced levels of CYT-1 and CYT-2 documented in treated cells by RT-PCR fully confirmed the downregulatory effect of Hh activation on ErbB-4 expression ( Figure 1c ).
Expression of ErbB-4 and its cytoplasmic splice variants in human MB
The Hh-dependent MBs from Ptc1 þ /À mice consistently exhibited low levels of ErbB-4 expression, but high receptor density has been reported in at least some human MBs (Gilbertson et al., 1997 (Gilbertson et al., , 1998 . To better characterize these tumors, we analysed the coexpression of ErbB-4 and Gli1 proteins in surgical samples of 26 human MBs. The results were suggestive of distinct tumor subsets (Figure 2a ): one characterized by weak ErbB-4 immunostaining and more intense positivity for Gli1 (Gli high tumors), the second represented by 11/26 (42%) tumors with virtually undetectable Gli1 expression and immunostaining for ErbB-4 that was appreciably stronger than that observed in normal adult cerebellar tissues (not shown). In this Gli low subset, ErbB-4 was preferentially localized within the nucleus. This observation is consistent with the reported predominance in human MBs of the cleavable JM-a isoform (Gilbertson et al., 2001) , whose intracellular domain is capable of relocating to the nucleus (Carpenter, 2003) .
Additional evidence of Hh-induced downregulation of ErbB-4 emerged from Q-RT-PCR assays of Daoy human MB cells in which Hh signalling was inhibited with KAAD-cyclopamine or forskolin (Taipale et al., 2000; Ruiz i Altaba et al., 2002) . Both drugs diminished Gli1 expression and produced similar and highly significant increases in mRNA for both the cytoplasmic ErbB-4 isoforms ( Figure 2b ).
Imbalance of CYT-1 and CYT-2 expression in Gli low -expressing human MB Although CYT-1 and CYT-2 were equally affected by Hh inhibition in vitro, a slightly different picture emerged when we evaluated expression of the cytoplasmic isoforms in the 26 human MBs. The ErbB-4 overexpression documented by immunohistochemistry in 11 of these tumors was mainly due to CYT-1 upregulation, whereas levels of CYT-2 mRNA resembled those found in normal adult cerebellum (Figure 3a and b).
Quantitative PCR analysis confirmed the existence of two distinct tumor subsets presumably characterized by different levels of Hh activity ( Figure 3c ). The 15 tumors with Gli high immunohistochemical patterns (Figure 2a ) all exhibited Gli1 levels that exceeded the mean level found in normal adult cerebella by at least two standard deviations, whereas the remaining 11 MBs presented levels well below this cutoff (Gli low subset). Compared with normal adult cerebellar tissues, in which CYT-2 expression clearly predominated over that of CYT-1 (Figure 3d ), nine (82%) of the 11 Gli low tumors were characterized by significantly upregulated CYT-1 expression that was almost identical to that observed in fetal cerebellum (Figure 3e ). In contrast, the Gli high MBs presented similar levels of CYT-1 and CYT-2 that were lower than those of fetal cerebellum ( Figure 3e ). The consistently higher CYT-1:CYT-2 ratios observed Cytoplasmic ErbB-4 isoforms in medulloblastoma E Ferretti et al in the Gli low tumor subset contrast with the results observed in vitro (Figure 2b ), where suppression of Hh signalling resulted in upregulation of both cytoplasmic ErbB-4 isoforms, and suggest that the mechanisms regulating ErbB-4 splice variants in vivo may be more complex.
CYT-1 expression and the CYT-1:CYT-2 ratio are inversely correlated with Gli1 expression in human MB To further support the relationships between Hh signalling and ErbB-4 expression, we assessed possible correlations between CYT-1 and CYT-2 expression and Gli1 levels in the 26 MB samples. Regression analysis disclosed a significant inverse correlation between Gli1 and CYT-1 mRNA levels (Po0.05), but Gli1 showed no correlation with CYT-2 (Figure 4a and b) .
Whereas normal adult cerebellum and Gli high tumors were both characterized by clear predominance of the CYT-2 isoform, the selective upregulation of CYT-1 in the Gli low tumor subset resulted CYT-1:CYT-2 ratios that were closer to 1. Indeed, the Gli low and Gli high MB subsets are clearly distinguished by non-overlapping CYT-1/CYT-2 ratios (Figure 4c ), and regression analysis disclosed an even more significant inverse correlation between these ratios and Gli1 levels (Po0.01) (Figure 4d ).
Differential regulation of MB cell proliferation and survival by ErbB-4 CYT-1 and CYT-2 isoforms To identify the effects of the two ErbB-4 isoforms on MB cell proliferation, we transfected D283 MB cells with JM-a-CYT-1 or JM-a-CYT-2 expression vectors (referred to hereafter as CYT-1 and CYT-2), and monitored BrdU incorporation following treatment with the ErbB-4-ligand, neuregulin-b3 (Zhang et al., 1997) (Figure 5a ). In control cells, which contained equal amounts of endogenous CYT-1 and CYT-2 (not shown), neuregulin had no significant effect on proliferation. Similar results were seen in cells overexpressing CYT-1. However, in CYT-2-transfected cells, the growth factor significantly downregulated proliferation. In the absence of neuregulin, no changes in proliferation were observed in CYT-1-or CYT-2-transfected cells.
To verify reports of the cytoplasmic isoforms' differential effects on cell survival (Kainulainen et al., 2000) , we evaluated responses to serum withdrawal (Figure 5b ) or etoposide treatment (Figure 5c ) in cells transfected with CYT-1 or CYT-2 and exposed to neuregulin. In cells overexpressing CYT-2, both apoptotic stimuli increased TdT-mediated dUTP nick end labeling (TUNEL)-and active caspase 3-positivity over levels observed in controls treated with neuregulin alone. In contrast, CYT-1 overexpression protected cells Cytoplasmic ErbB-4 isoforms in medulloblastoma E Ferretti et al from both types of apoptosis, as demonstrated by the significant reductions in TUNEL and caspase positivity compared with those observed in CYT-2-overexpressing cells. The main structural difference between the two CYT splice variants is a PI3K-binding site in the cytoplasmic tail of CYT-1, which allows this isoform to activate antiapoptotic signalling mediated by Akt (Elenius et al., 1999) . In fact, the Akt inhibitor, LY294002, abrogated the protective effects of CYT-1 against cell death provoked by serum withdrawal (Figure 5d ) or etoposide (Figure 5e ), but had no effect on apoptosis in CYT-2-transfected cells.
These findings highlight the distinct biological properties of the cytoplasmic ErbB-4 isoforms in MB cells. These functional differences could justify the selective upregulation in MB of ErbB-4 CYT-1, which confers a relatively apoptosis-resistant phenotype, and the counter-selection of CYT-2, which mediates neuregulindependent growth suppression.
CYT-1/CYT-2 ratio and prognostic markers in human MB
To identify the possible prognostic implications of the functional differences discussed above, we analysed the CYT-1:CYT-2 ratios of the 26 human MB specimens as a function of histotype. The mean ratio for tumors with the highly aggressive anaplastic/large-cell phenotype was significantly higher (Po0.05) than that of the desmoplastic MBs (Figure 6a ). We then measured levels of mRNA for the other two members of the ErbB receptor family that form heterodimers with ErbB-4, that is, ErbB-2, an established marker of poor prognosis in MB, and ErbB-3. The expression of the latter was significantly downregulated in almost all the MBs (Figure 6b ) whereas ErbB-2 levels were increased in 73% of the Gli low tumors and about 30% of those with a Gli high phenotype (Figure 6c ). ErbB-2 levels were also positively correlated with the CYT-1:CYT-2 ratios in human MB samples (Po0.001) (Figure 6d ). Collectively, these findings suggest that the ErbB-4 CYT1/ CYT2 ratio may be an indicator of MB aggressivity.
Discussion
The ErbB signal is crucial for several developmental programs. Its involvement in brain development is reflected in the architectural anomalies observed in the cerebella of ErbB-4 À/À /HER4 heart mice (Tidcombe et al., 2003) and in the ability of neuregulin, the ErbB-4 ligand, to induce differentiation of cerebellar GCPs (Rieff et al., 1999) . The importance of the ErbB pathway is also evident in MB, where the simultaneous overexpression of ErbB-4 and ErbB-2 results in a particularly aggressive tumor phenotype (Gilbertson et al., 1998) . However, our understanding of the relevance of ErbB-4 signalling in these tumors (and others as well) is far from complete. Progress in this area has been hampered in part by difficulties related to the presence of ErbB-4 isoforms generated by alternative splicing. Their contributions to signalling are mediated, in fact, by isoform-specific coupling to various pathways (Carpenter, 2003) . Moreover, it is unclear how ErbB-4 signals interact with those of other pathways whose deregulation plays an important role in the development of MB.
We documented reduced expression of both ErbB-4 CYT1 and CYT2 in MBs from Ptc-1 þ /À mice, which suggested that Hh activation might downregulate ErbB-4 expression. This hypothesis is compatible with the mutually exclusive expression of ErbB-4 and Gli1 we observed in murine cerebellar GCPs from the EGL. The presence of Gli1-positive cells in the outer EGL is consistent with the active proliferation that occurs in this zone. It is followed by a program of differentiation, which begins as GCPs move into the inner EGL, where ErbB-4 staining predominated. The downregulating effect of Hh on ErbB-4 is also strongly supported by the decreased ErbB-4 expression in cultured mouse GCPs treated with Shh and the increases observed after cyclopamine-induced inhibition of Hh signalling.
Our analysis of human MB specimens revealed two distinct subsets characterized by high-versus low-level Hh signalling. As expected (based on the findings discussed above), the Gli high tumors were consistently characterized by low-normal levels of ErbB-4, whereas those with low Gli1 levels presented high expression of ErbB-4. In the latter case, however, the upregulation surprisingly involved only ErbB-4 CYT-1. Although the absence of Hh signalling clearly favors ErbB-4 expression in vitro and in vivo, the preferential CYT-1 splicing seems to be an exclusively in vivo effect. Although its cause remains obscure, it seems clear that increased expression of CYT-1 could provide cancer cells with selection advantages with respect to normal cells. The cytoplasmic domain of this isoform includes the YTPM consensus motif for PI3K binding (amino acids 1046-1061), which is missing in CYT-2 (Elenius et al., 1999) . Phosphorylation of the tyrosine in position 1056 (as a result of ligand/receptor interaction) creates a binding site with high affinity for the SH-2 domain of PI3K and subsequent coupling with the Akt antiapoptotic signalling cascade (Elenius et al., 1999; Kainulainen et al., 2000) . Because ERBb-4 CYT-2 lacks this PI3K-binding domain, it is incapable of mediating neuregulin-induced survival during serum starvation (Kainulainen et al., 2000) . Our findings are consistent with this observation: apoptosis induced in MB cells by starvation or etoposide was inhibited by neuregulin only in the presence of CYT-1 upregulation, and this survival-promoting effect was abrogated by the Akt inhibitor, LY294002. Although recent findings indicate that CYT-2 is also able to activate PI3K/Akt signals, this capacity depends on its heterodimerization with the ErbB-3 receptor (Gambarotta et al., 2004) , which was virtually undetectable in our human MB specimens. In terms of tumor progression, an additional advantage of enhanced CYT-1 expression is reflected by the persistence of active proliferation in CYT-1-overexpressing MB cells after neuregulin stimulation, which produced a clear growth arrest in cells transfected with the CYT-2 isoform.
These observations suggest that increases in the ErbB-4 CYT-1:CYT-2 ratio represent an alteration that occurs specifically in MB and endows the receptor with properties favoring tumor progression. This hypothesis is supported by the correlation we observed between CYT-1 overexpression and MB features predictive of unfavorable outcomes, such as the anaplastic histotype and ErbB-2 expression. It is also consistent with the preliminary 24-month follow-up data that are available for nine of the MB patients considered in this study. Four of the five patients, whose tumors exhibited low CYT-1:CYT-2 ratios, are still alive. Of the four patients with high CYT-1:CYT-2 ratio tumors, three have died and the fourth has recurrent disease (data not shown).
In conclusion, our data suggest that selective maintenance of high ErbB-4 CYT-1 expression in cerebellar GCPs represents an alternative pathway for MB tumorigenesis that is particularly relevant in tumors characterized by low-level Hh signalling. In the model we propose (Figure 7 ), upregulated expression of the CYT-1 isoform as a consequence of the lack of Hh-dependent inhibitory signals represents a potential advantage for tumor cells. With respect to the normal cell population, in which there is a more substantial excess of CYT-2, MB cells with higher levels of CYT-1 are less susceptible to neuregulin-induced inhibition of proliferation and more responsive to the growth factor's protective effects during proapoptotic conditions.
Materials and methods

Mouse and human tissue samples
We analysed normal cerebella from CD1 mice (Charles River, Wilmington, MA, USA) and 14 MB specimens from Ptc1 þ /À mice (Hahn et al., 1998; Pazzaglia et al., 2002) . Surgical specimens of primary MBs (five desmoplastic, 15 classic and six anaplastic/large cell, according to World Health Organization criteria) (Giangaspero et al., 2002) were collected from 23 male and three female patients with Institutional Review Board approval. Nine tumors were Chang stage M0-M1, four were stage M2-M3 and the stages of the remaining 13 were unknown. Thirteen patients had received chemotherapy, and six had also undergone radiation therapy. RNAs of normal human cerebella (adult and fetal) were from Biocat (Heidelberg, Germany).
Cell cultures and treatments D283 and Daoy cells (ATCC, L.G.C., Promochem, Mi, Italy) and cerebellar GCPs isolated from P4 mice were cultured as described previously (Di Marcotullio et al., 2004; Argenti et al., 2005) . Recombinant mouse Shh N-terminal peptide, KAAD-cyclopamine and forskolin were from R&D systems (Mi, Italy), Chemicon (Temecula, CA, USA) and SigmaAldrich (Mi, Italy), respectively. D283 cells were transfected with full-length JM-a-CYT-1 or JM-a-CYT2 cDNAs (Omerovic et al., 2004) using Lipofectamine plus or Lipofectamine 2000 (Invitrogen, Mi, Italy) according to the manufacturer's instructions. Twenty-four and 48 h after transfection and treatment with Neuregulin-b3 (Upstate, Dundee, UK), proliferation was evaluated by BrdU incorporation (10 h pulse). Cells were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100, labelled with anti-GFP (control) or anti-ErbB-4 (Santa Cruz, CA, USA) antibodies and re-fixed for 10 min. BrdU was detected with the BrdU labelling and detection assay (Roche, Monza, Italy) was performed according to the manufacturer's instructions.
RNA isolation and RT-PCR analysis RNA isolation, cDNA synthesis and PCR reactions for murine ErbB-4 CYT isoforms were performed as described previously (Elenius et al., 1999; Argenti et al., 2005) .
Human primers were: ErbB-4-Fw: 5 0 -ATCTCTTGGATGA AGAGGATTTGG-3 0 ; ErbB-4-Rev: 5 0 -GTCATCAAAAATC Figure 7 Hypothetical model of the role of ErbB-4 in MB growth.
In the MB subset represented on the right, Hh-signalling downregulates ErbB-4 expression and promotes cell growth and survival via activation of Gli1-stimulated transcription. In the subset represent on the left, low Hh signalling allows upregulation of ErbB-4 expression that results in high receptor density and a tumor-specific increase in the CYT-1:CYT-2 ratio (normally o1). The latter alteration is the consequence of the selection advantage conferred by CYT-1-dependent promotion of cell survival and the reduced inhibition of cell proliferation caused by the relatively low levels of CYT-2.
Cytoplasmic ErbB-4 isoforms in medulloblastoma E Ferretti et al TCAGCAGTAGC-3 0 . The amplification products measured 295 bp (CYT-1) and 240 bp (CYT-2), and specificity was verified by sequencing. Semiquantitative evaluation of PCR products was based on optical density values normalized to b-actin.
Quantitative RT-PCR analysis of Gli1, CYT-1, CYT-2, ErbB1, ErbB-2, ErbB-3 and ErbB-4 mRNA was performed on cDNAs using the ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Monza, Italy), with designed (CYT-1 and CYT-2) and Assay-on-Demand reagents. The oligos used were (probes in parentheses):
ErbB-4-CYT-1, F5 0 -ACAGCCCTCCTCCTGCCT-3 0 , R5 0 -CTCCATCTCGGTATACAAACTG-3 0 , (5 0 -CACCCCCATG TCAGG-3 0 , junction between exons 25/26); ErbB-4-CYT-2, F5 0 -TTCCAGAGCAAGAATTGACTCG-3 0 , R5 0 -CTCCTTG TTCAGCAGCAAAACC-3 0 , (5 0 -ATAGGAACCAGTTTGT ATACCGA-3 0 , junction between exons 25/27). Each amplification reaction was performed in triplicate, and the average of the three threshold cycles was used to calculate the amount of transcript in the sample (SDS software, ABI). mRNA quantification was expressed in arbitrary units as the ratio of the sample quantity to that of the calibrator or to the mean values of controls samples. All values were normalized to three endogenous controls, GAPDH, b-actin and HPRT.
Immunohistochemistry, immunofluorescence and apoptosis assays Rabbit polyclonal anti-ErbB-4 and anti-Gli1 antibodies (Santa Cruz) were used for immunohistochemical staining of 3 mmthick sections from formalin-fixed paraffin-embedded tissues. Staining was revealed by the streptavidin-biotin-peroxidase system (DAKO, Glostrup, Denmark) with diaminobenzidine (Lab. Vision Corporation, Freemont, CA, USA). Briefly, deparaffinized re-hydrated sections were incubated overnight with anti-ErbB-4 and then for 1 h at 41C with biotinylated anti-rabbit antibody (Vector Laboratories, Burlingane, CA, USA). Sections were counterstained with hematoxylin. Immunofluorescence and apoptosis assays were performed as described previously (Argenti et al., 2005) . TUNEL-positive cells or caspase-3 expression in either CYT-1-or CYT-2-transfected cell was determined by coimmunostaining with anti-ErbB-4 or anti-GFP antibodies and TUNEL labelling or anti-active caspase-3, respectively.
Statistical analysis
Results are expressed as means7s.d. from an appropriate number of experiments indicated in figure legends. Statistical differences were analysed by the Mann-Whitney U-test for non-parametric values; MB parameters were analysed by simple regression and Fisher tests using StatView 4.1 software (Abacus Concepts, Berkeley, CA, USA).
